Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer.

ABSTRACT: In selected patients with stage IV gastric cancer, radical surgery after conversion therapy may increase survival benefit; however, there is currently no standard protocol for conversion therapy. We explored the feasibility and efficacy of sintilimab plus two-drug chemotherapy (S-1 plus nab-paclitaxel) and apatinib as conversion therapy in patients with stage IV gastric cancer in China. This was a prospective, single-arm, single-center, phase 2 study. The primary endpoint was the R0 conversion rate, defined as the proportion of R0 surgical patients to the total number of patients treated. Of 56 patients screened, 47 were enrolled, received preoperative treatment, and were evaluated for tumor response. Most patients (28/47; 59.6%) had two or three unresectable factors. The objective respons

SUBMITTER: Liu Y 

PROVIDER: S-EPMC12375854 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature